Efficacy of icatibant treatment in patients with hereditary angio-oedema type I resistant to treatment with C1 inhibitor concentrate
Funding sources: No specific grant or funding was associated with this study. Financial support for development of this manuscript was provided by Shire Human Genetic Therapies, Inc.
Conflicts of interest: L.B. and I.B.-G. have received consultancy fees from CSL Behring and Shire Human Genetic Therapies, Inc.
Data from this report were presented at the 18th Congress of the European Academy of Dermatology and Venereology, Berlin, Germany, 7–11 October 2009.
No abstract is available for this article.